{"id":"drug-ipratropium-atroventtm","safety":{"commonSideEffects":[{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Palpitations"}]},"_chembl":{"chemblId":"CHEMBL1621597","moleculeType":"Small molecule","molecularWeight":"332.46"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ipratropium competitively antagonizes acetylcholine at M3 muscarinic receptors on airway smooth muscle and mucus glands. This prevents acetylcholine-induced bronchoconstriction and reduces mucus production, leading to bronchodilation and improved airflow. As a quaternary ammonium compound, it is poorly absorbed systemically and acts locally in the lungs when inhaled.","oneSentence":"Ipratropium is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the airways to reduce bronchoconstriction and mucus secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:35:40.111Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma"},{"name":"Rhinorrhea associated with allergic and non-allergic rhinitis"}]},"trialDetails":[{"nctId":"NCT01415518","phase":"PHASE4","title":"Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-09-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":581}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Drug: ipratropium (AtroventTM)","genericName":"Drug: ipratropium (AtroventTM)","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ipratropium is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the airways to reduce bronchoconstriction and mucus secretion. Used for Chronic obstructive pulmonary disease (COPD), Asthma, Rhinorrhea associated with allergic and non-allergic rhinitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}